Lecap Asset Management Ltd. Sells 58,387 Shares of Pfizer Inc. $PFE

Lecap Asset Management Ltd. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 71.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,806 shares of the biopharmaceutical company’s stock after selling 58,387 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Pfizer were worth $553,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter worth about $28,000. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. WPG Advisers LLC purchased a new position in Pfizer in the first quarter worth about $35,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer in the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.5%

Shares of PFE opened at $27.08 on Friday. The firm has a market capitalization of $153.94 billion, a price-to-earnings ratio of 14.40, a PEG ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a 50-day moving average of $24.62 and a 200 day moving average of $24.14.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.29.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.